Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.
Tassinari
D
D
Pneumo-Oncology Unit, Department of Oncology. Electronic address: dtassinari@rimini.com.
Drudi
F
F
Pneumo-Oncology Unit, Department of Oncology.
Lazzari-Agli
L
L
Pneumo-Oncology Unit, Department of Oncology.
Tombesi
P
P
Department of Internal Medicine, Arcispedale S.Anna, Ferrara, Italy.
Sartori
S
S
Department of Internal Medicine, Arcispedale S.Anna, Ferrara, Italy.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D000077143:Docetaxel; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
D043823:Taxoids; D000077143:Docetaxel